

# Post-reg Foundation Programme Handbook – FP Part 1 (FP1)

2024/25

17FP1HB ©NICPLD February 2025

#### Preface

Welcome to the Northern Ireland Centre for Pharmacy Learning and Development (NICPLD) Post-reg Foundation Programme (PRFP) for patient-focused pharmacists.


The NICPLD PRFP covers the outcomes of the Royal Pharmaceutical Society (RPS) Post-registration Foundation Pharmacist Curriculum<sup>1</sup> in all five domains:

- Person-centred care & collaboration
- Professional practice
- Leadership & management
- Education
- Research

These outcomes are covered in two parts:

- Part 1 safe and effective patient care
- Part 2 proficient patient care

Part 2 (FP2) builds upon Part 1 (FP1 – Fundamentals of Pharmacy Practice), as illustrated in the diagram below, and pharmacists must have completed FP1 before commencing FP2.



This handbook provides background information and details about the content and structure of Part 1 of the NICPLD Post-reg Foundation Programme (FP1).

registration Foundation Pharmacist Curriculum outcomes and descriptors.

The FP1 outcomes are based on the 55 learning outcomes of the GPhC Standards for the initial education and training of pharmacists (IETP)<sup>2</sup>, which we have <u>mapped</u> to the RPS Post-registration Foundation Pharmacist Curriculum. FP2 covers the remaining RPS Post-

### Acknowledgements

We would like to thank stakeholders for their contribution in shaping the format and content of the NICPLD Post-reg Foundation Programme. We would also like to thank all the individuals involved in developing and implementing former versions of the NICPLD Foundation Programme.

# Contents

Preface	1
Contents	2
1. Introduction	3
2. Who can enrol onto FP1?	3
3. Learning outcomes	3
4. Practice areas	6
5. Practice activities	6
6. Practice portfolio	9
7. FP1 workshops/webinars	10
8. FP1 online courses and resources	14
9. FP Educational Supervisor (ES)	14
10. FP Practice Supervisor (PS)	14
11. FP1 assessment process	
12. Recognition of Prior Learning (RPL)	16
13. Appeals procedure	18
14. Plagiarism	18
15. NICPLD contact details	18
16. References	18

#### 1. Introduction

Part 1 of the NICPLD Post-reg Foundation Programme (FP1) aims to provide structured workplace learning experiences to support patient-focused pharmacists in Northern Ireland to deliver safe and effective care to individual patients. The emphasis in FP1 is on developing competence (the ability to perform consistently to the required standard) using authentic activities in practice (rather than classroom activities).

FP1 is intended to be flexible to accommodate individual learning needs and service requirements. During FP1, pharmacists develop a portfolio and undertake practice activities which help them to develop and demonstrate their competence in a range of different practice areas. How this works in practice will depend on both the workplace establishment and the individual pharmacist. Reflective practice is encouraged and FP1 pharmacists are expected to maintain appropriate Continuing Professional Development (CPD) records.

Throughout FP1, pharmacists are supported in the workplace by an Educational Supervisor (ES). In larger workplace establishments the ES may be assisted by local Practice Supervisors (PS) who are able to support the FP1 pharmacist's learning and development and observe their practice on a more routine basis. There are also workshops/webinars and online courses for FP1 pharmacists and a formal assessment process.

#### 2. Who can enrol onto FP1?

Part 1 of the NICPLD Post-reg Foundation Programme (FP1) is open to all registered patient-focused pharmacists working in Northern Ireland. Pharmacists wishing to enrol onto FP1 must complete and submit an application form, which can be accessed via the NICPLD website, <a href="https://www.nicpld.org">www.nicpld.org</a>.

Applications are accepted twice a year; closing dates in 2024/5 are 12 noon on Wednesday 28<sup>th</sup> August 2024 (cohort 5) and 12 noon on Wednesday 19<sup>th</sup> February 2025 (cohort 6).

# 3. Learning outcomes

The FP1 outcomes are based on the 55 learning outcomes of the new GPhC Standards for the initial education and training of pharmacists (IETP)<sup>2</sup>, in the following four domains:

- Person-centred care and collaboration
- Professional practice
- Leadership and management
- Education and research

These are listed on the following pages.

#### Person-centred care and collaboration **Professional Practice** 1. Demonstrate empathy and keep the person at the 15. Demonstrate the values, attitudes and behaviours centre of their approach to care at all times expected of a pharmacy professional at all times 2. Work in partnership with people to support and 16. Apply professional judgement in all circumstances, empower them in shared decision-making about taking legal and ethical reasoning into account their health and wellbeing 17. Recognise and work within the limits of their 3. Demonstrate effective communication at all times knowledge and skills, and get support and refer to and adapt their approach and communication others when they need to style to meet the needs of the person 18. Take responsibility for all aspects of pharmacy Understand the variety of settings and adapt their services, and make sure that the care and services communication accordingly provided are safe and accurate Proactively support people to make safe and 19. Take responsibility for all aspects of health and safety effective use of their medicines and devices and take actions when necessary, particularly but not Treat people as equals, with dignity and respect, exclusively during the COVID-19 pandemic and meet their own legal responsibilities under 20. Act openly and honestly when things go wrong and equality and human rights legislation, while raise concerns even when it is not easy to do so respecting diversity and cultural differences 21. Apply the science behind pharmacy in all activities 7. Obtain informed consent before providing care 22. Demonstrate how the science behind pharmacy is and pharmacy services applied in the discovery, design, development and 8. Assess and respond to the person's particular safety testing of medicines and devices health risks, taking account of individuals' 23. Recognise the technologies that are behind protected characteristics and background developing advanced therapeutic medicinal products Take responsibility for ensuring that personal and precision medicines, including the formulation, values and beliefs do not compromise personsupply and quality assurance of these therapeutic centred care 10. Demonstrate effective consultation skills, and in 24. Keep abreast of new technologies and use data and partnership with the person, decide the most digital technologies to improve clinical outcomes and appropriate course of action patient safety, keeping to information governance 11. Take into consideration factors that affect principles people's behaviours in relation to health and 25. Apply pharmaceutical principles to the safe and wellbeing effective formulation, preparation, packaging and 12. Take an all-inclusive approach to ensure the most disposal of medicines and products appropriate course of action based on clinical, 26. Consider the quality, safety and risks associated with legal and professional considerations medicines and products and take appropriate action 13. Recognise the psychological, physiological and when supplying and prescribing them 27. Take responsibility for the legal, safe and efficient physical impact of prescribing decisions on people 14. Work collaboratively and effectively with other supply, prescribing and administration of medicines members of the multi-disciplinary team to ensure and devices 28. Demonstrate effective diagnostic skills, including high-quality, person-centred care, including continuity of care physical examination, to decide the most appropriate course of action for the person. During the COVID-19 pandemic all relevant precautions must be taken to ensure the safety of the patient and foundation trainee when physical contact is necessary 29. Apply the principles of clinical therapeutics, pharmacology and genomics to make effective use of medicines for people 30. Appraise the evidence base and apply clinical

©NICPLD February 2025

reasoning and professional judgement to make safe and logical decisions which minimise risk and

31. Critically evaluate and use national guidelines and clinical evidence to support safe, rational and cost-

optimise outcomes for the person

effective procurement for the use, and prescribing of,
medicines, devices and services
32. Accurately perform calculations
33. Effectively promote healthy lifestyles using evidence-
based techniques
34. Apply the principles of effective monitoring and
management to improve health outcomes
35. Anticipate and recognise adverse drug reactions, and
recognise the need to apply the principles of
pharmacovigilance
36. Apply relevant legislation and ethical decision-making
related to prescribing, including remote prescribing
37. Prescribe effectively within the relevant systems and
frameworks for medicines use
38. Understand clinical governance in relation to
prescribing
39. Take responsibility for people's health records,
including the legality, appropriateness, accuracy,
security and confidentiality of personal data
40. Understand and implement relevant safeguarding
procedures, including local and national guidance in
relation to each person
41. Effectively make use of local and national health and
social care policies to improve health outcomes and
public health, and to address health inequalities
42. Proactively participate in the promotion and
protection of public health in their practice
43. Identify misuse of medicines and implement effective
strategies to deal with this
44. Respond appropriately to medical emergencies,
including the provision of first aid

	Leadership and management	Education and research
45.	Demonstrate effective leadership and management skills as part of the multi-disciplinary team	<ul><li>53. Reflect upon, identify, and proactively address their learning needs</li><li>54. Support the learning and development of others,</li></ul>
46.	Make use of the skills and knowledge of other members of the multi-disciplinary team to manage resources and priorities	including through mentoring  55. Take part in research activities, audit, service evaluation and quality improvement, and
47.	Develop, lead and apply effective strategies to improve the quality of care and safe use of medicines	demonstrate how these are used to improve care and services
48.	Actively take part in the management of risks and consider the impacts on people	
49.	Use tools and techniques to avoid medication errors associated with prescribing, supply and administration	
50.	Take appropriate actions to respond to complaints, incidents or errors in a timely manner and to prevent them happening again	
51.	Recognise when and how their performance or that of others could put people at risk and take appropriate actions	

52. Demonstrate resilience and flexibility, and apply effective strategies to manage multiple priorities, uncertainty, complexity and change

# 4. Practice areas

FP1 pharmacists gain experience in four practice areas:

- Optimising medicines use (OMU)
- Safe and effective provision of medicines (SEPM)
- Governance and quality improvement (GQI)
- Promoting public health (PPH)

Each practice area has a specified set of practice activities which help individuals to cover the FP1 learning outcomes. These are outlined below.

#### 5. Practice activities

Practice activities provide a 'scaffold' which allows the learner to construct the relevant knowledge and skills<sup>3</sup>. The FP1 practice activities are intended to help the pharmacist to generate quality evidence which they can upload into their portfolio to demonstrate that they have covered the FP1 learning outcomes (LOs). The RPS recommends that quality evidence in a portfolio should include the following three components, which they refer to as a 'triad of evidence'4:

**Output** – this is the main piece of output evidence, e.g log form, case study, audit, SOP, etc.:

**Reflection** – the output evidence should be supported by a reflective record detailing how the relevant LOs have been demonstrated, and any learning needs identified;

**Corroboration** – an ES or PS should observe practice +/or provide written feedback to corroborate the output evidence.

The FP1 practice activities (PAs) are listed on the following pages. Further information on the practice activities, including downloadable templates, can be accessed via the NICPLD website, <a href="https://www.nicpld.org">www.nicpld.org</a>.

FP1 pharmacists do NOT need to provide evidence for learning outcome 37 as this can only be demonstrated by a registered prescriber. If they wish to train as a prescriber, LO 37 will be covered in the Independent Prescribing (IP) course.

Their practice activities need to include **two examples of accurately performing calculations in practice** to demonstrate that they have covered LO 32. They should also upload their **First Aid certificate** (or equivalent) to demonstrate that they have covered LO 44. If a certificate is not available then please upload some form of evidence a course was completed e.g. a testimonial or statement from previous workplace.

# Optimising medicines use (OMU)

Practice activity	Description	Evidence required (recording templates are available on the NICPLD website)
*Medication reviews	The pharmacist should record 4 patient-facing medication reviews demonstrating a range of patient types. Patients should be typical patients with multi-morbidities and polypharmacy.	4 x medication reviews
*Observed medication reviews	The pharmacist should be observed undertaking 2 of the patient-facing medication reviews.	2 x observed medication reviews
*Medication record	The pharmacist should reflect on their experience of ensuring that patients' health/medication records/documents (including those used for transfer of care between clinical settings) are completed accurately and in accordance with GDPR.	1 x reflective record
*Provision of person- centred information	The pharmacist should provide accurate, timely, evidence-based information to patients/carers +/or healthcare professionals (in response to queries relating to medicines or symptoms).	5 x examples in total
NICPLD eLearning course – electrolytes, liver and kidney function tests	The pharmacist should complete this eLearning course.	CPD cycle (include your MCQ score and date/certificate of completion)
NICPLD eLearning course – Iron studies & anaemia	The pharmacist should complete this eLearning course.	CPD cycle (include your MCQ score and date/certificate of completion)

<sup>\*</sup> A fully completed and signed NI Clinical Induction Passport (secondary care) can be uploaded to the portfolio and used to demonstrate completion of these practice activities.

# Safe and effective provision of medicines (SEPM)

Practice activity	Description	Evidence required (recording templates are available on the NICPLD website)
Checking accuracy	The pharmacist should complete a 100-item log demonstrating their ability to accuracy check items dispensed by others against a range of prescription types AND reflect on their accuracy checking experience.	Completed 100 item log PLUS 1 x reflective record.  Local log templates can be used/NICPLD templates provided on the FP1 website.

Clinical screening	The pharmacist should complete a 100-item log demonstrating their ability to clinically screen medicines prescribed for a range of patient types AND reflect on their clinical screening experience.	Completed 100 item log PLUS 1 x reflective record  Local log templates can be used/NICPLD templates provided on the FP1 website.
Procurement activity	The pharmacist should reflect on a procurement activity they have been involved in (e.g sourcing and supplying a pharmacy special/unlicensed medicine).	1 x reflective record
Managing workflow	The pharmacist should reflect on their experience of managing the workflow in their workplace.	1 x reflective record
Disposal of medicines	The pharmacist should reflect on their experience of disposing of a range of different medicine types, such as returned/unused patient medicines, controlled drugs, expired medicines.	1 x reflective record

# Governance and quality improvement (GQI)

Practice activity	Description	Evidence required (recording templates are available on the NICPLD website)
Undertake an audit	The pharmacist should undertake an audit in practice. This includes setting the audit standard, defining the methodology, collecting data, reviewing the data with reference to the audit standard, and making appropriate recommendations.	1 x audit template
Recording of near misses and incidents	The pharmacist should routinely report near misses and incidents in accordance with the established procedures within the workplace.	1 x reflective record
Yellow card reporting	The pharmacist should appreciate the range of problems/incidents to be reported via the Yellow Card reporting system. If they do not experience a problem/incident to be reported, they should discuss a theoretical incident and how it would be reported in practice.	1 x reflective record
Using technology to enhance patient care	The pharmacist should reflect on their experience of using technology to enhance patient care.	1 x reflective record
Teaching activity	The pharmacist should develop a teaching session and deliver this to others. This can relate to a range of different activities including medicines	1 x teaching observation

	use, reporting back on medicines incidents, reporting back on findings of audit etc.	
Collaborative working	The pharmacist should provide an example of how they have worked collaboratively as part of a multidisciplinary team (MDT) to optimise patient outcomes.	1 x reflective record

# Promoting public health (PPH)

Practice activity	Description	Evidence required (recording templates are available on the NICPLD website)
Safeguarding activities	The pharmacist should record a case-based discussion of a safeguarding case they have encountered (e.g. safeguarding of children or vulnerable adults).  If the pharmacist has not encountered a case, they can complete the 3 scenarios provided on the NICPLD website instead. If they completed these as part of the NICPLD FTY year, they should complete a 'Safeguarding cases – confirmation of completion during NICPLD FTY' form instead, which is available on the website.  See page 10 for additional notes.	Safeguarding CbD template or Safeguarding cases – confirmation of completion during NICPLD FTY form
Minimising the misuse of medicines	The pharmacist should reflect on their experience of minimising the misuse of medicines such as opioids or Beta-2-agonists.	1 x reflective record
Promoting the health of the public	The pharmacist should reflect on their experience of promoting the health of the public (e.g., in a health promotion/awareness day/campaign, or an activity to reduce antimicrobial resistance).	1 x reflective record

# 6. Practice portfolio

FP1 pharmacists record evidence of their learning achievements against the FP1 learning outcomes in an online portfolio. The NICPLD FP1 portfolio user guide can be downloaded at <a href="https://www.nicpld.org">www.nicpld.org</a>. The FP1 pharmacist, with the help of their ES, can use the practice portfolio to assess their baseline competency status at T1 for the FP1 learning outcomes in each domain using the following assessment ratings:

	Assessment rating	Definition
0	I have yet to encounter an opportunity	I have not yet met the standard
1	I rarely meet the standard expected	I meet the standard approximately <b>0-24</b> % of the time
2	I sometimes demonstrate the standard expected	I meet the standard approximately <b>25-50</b> % of the time
3	I usually demonstrate the standard expected	I meet the standard approximately <b>51-84</b> % of the time
4	I consistently demonstrate the standard expected (repeatedly and reliably)	I meet the standard approximately <b>85-100%</b> of the time

This enables them to identify their individual learning needs by considering the learning outcomes where they have not yet achieved the required standard (i.e an assessment rating of 4). FP1 pharmacists are encouraged to record these learning needs on a Personal Development Plan (PDP) (available at <a href="www.nicpld.org">www.nicpld.org</a>). In addition, each learning need should be recorded in detail in the 'reflection' stage of a new Continuing Professional Development (CPD) cycle. The PDP helps the FP1 pharmacist to plan and prioritise how and when they will address their learning needs.

During their experiential learning the FP1 pharmacist collects evidence to demonstrate their developing competence and stores it in their practice portfolio. This will include evidence that they have completed the practice activities, plus any other relevant forms of supportive evidence such as reflective records. The evidence is mapped against the relevant learning outcomes in their practice portfolio (NB one piece of evidence may be used to demonstrate competence against more than one learning outcome).

Please note when the FP1 pharmacist is mapping their evidence to the learning outcomes, they should ensure they review the wording of the learning outcome carefully. If the learning outcome is at a "does" level, theoretical evidence e.g. safeguarding scenarios provided by NICPLD, will not be awarded the learning outcomes.

For those pharmacists that have completed an e-learning program pertaining to advanced therapeutic medicinal products as part of their FTY year, they can upload their evidence of completion to their portfolio to demonstrate learning outcomes 22 and 23.

It is recommended that the FP1 pharmacist meets regularly with their ES (e.g monthly) to discuss their progress. At these meetings, the ES will help the FP1 pharmacist to assess their competency status, again using the assessment ratings above, and to update their portfolio and their PDP. For the learning outcomes where they have yet to meet the expected standard, FP1 pharmacists will have the opportunity to discuss with their ES how they plan to develop competence in that area.

Each domain is completed when the FP1 pharmacist has:

- an assessment rating of 4 at T4 for each of the learning outcomes;
- at least one piece of supporting evidence for each of the learning outcomes.

When all four domains and all practice activities have been completed satisfactorily, the FP1 pharmacist can submit their completed portfolio to NICPLD for a Foundation Portfolio Review (FPR) assessment. The FPR assessment process is described in detail in section 11.1

# 7. FP1 workshops/webinars

To support FP1 pharmacists, NICPLD offers workshops/webinars relating to the four practice areas. These cover important subjects and skills that may not be covered specifically in the workplace. Attendance at each workshop/webinar is expected for completion of the programme. FP1 pharmacists will be enrolled automatically and will receive reminders via email in advance of the workshop/webinar taking place. FP1 workshops/webinars use case-based discussions in small groups to help pharmacists to apply their learning. For the webinars, FP1 pharmacists must switch on their cameras and microphones to participate in the group discussions.

The FP1 workshops/webinars taking place in 2024/5 for cohorts 5 and 6 are listed on the following pages.

# Cohort 5:

FP1 workshop / webinar	Format	
		<b>When:</b> 18 <sup>th</sup> September 2024 10am-12pm
FP1 Induction	Face to face	Where: Stranmillis College Belfast
TTT III doction	workshop	Pre-requisites:  1) Read through all materials emailed
		When: 18th September 2024 1pm-4pm
		Where: Stranmillis College Belfast
Medicines reconciliation & review	Face to face workshop	Pre-requisites:  1) Read through the medicines reconciliation and review preworkshop presentation and accompanying notes.  2) Prepare case studies.
		When: 17 <sup>th</sup> October 2024 10am-12pm
Clinical Lab Tests	Webinar	Pre-requisites:  1) Complete 2 NICPLD eLearning courses:  • Electrolytes, liver and kidney function tests  • Iron studies & anaemia  2) Prepare case studies  3) Download the Zoom app
		When: 6 <sup>th</sup> November 2024 10am-12pm
Audit	Webinar	Pre-requisites: 1) Read through all pre-webinar materials emailed 2) Prepare case study
		When: 4 <sup>th</sup> December 2024 10am-12pm
Effective Professional Practice Part 1	Mahin	Pre-requisites:
(part 2 will be delivered in FP2)	Webinar	Read through all pre-webinar materials emailed
FP1 assessment preparation		When: 12th December 2024 10am-12pm
	Webinar	Pre-requisites:  1) Read through all pre-webinar materials emailed
Q&A	Webinar	<b>When:</b> 7 <sup>th</sup> February 2025 10am-10.30am
Portfolio submission		19 <sup>th</sup> March 2025 12pm

# Cohort 6:

FP1 workshop / webinar	Format	
		When: 5 <sup>th</sup> March 2025 10am-12pm
FP1 Induction	Face to face workshop	Where: Stranmillis College Belfast  Pre-requisites:  1) Read through all materials emailed
		When 5th March 2005 In 22 42 22
Medicines reconciliation & review	Face to face workshop	<ul> <li>When: 5<sup>th</sup> March 2025 1pm-4pm</li> <li>Where: Stranmillis College Belfast</li> <li>Pre-requisites: <ol> <li>Read through the medicines reconciliation and review pre workshop presentation and accompanying notes.</li> </ol> </li> <li>Prepare case studies.</li> </ul>
		When: 2rd April 2025 10cm 12cm
Clinical Lab Tests	Webinar	<ul> <li>When: 3rd April 2025 10am-12pm</li> <li>Pre-requisites: <ol> <li>Complete 2 NICPLD eLearning courses:</li> <li>Electrolytes, liver and kidney function tests</li> <li>Iron studies &amp; anaemia</li> </ol> </li> <li>Prepare case studies</li> <li>Download the Zoom app</li> </ul>
Audit	Webinar	When: 15 <sup>th</sup> May 2025 10am-12pm  Pre-requisites: 1) Read through all pre-webinar materials emailed 2) Prepare case study
Effective Professional Practice Part 1  (part 2 will be delivered in FP2)	Webinar	When: 11th June 2025 10am-12pm  Pre-requisites:  1) Read through all pre-webinar materials emailed
FP1 assessment preparation	Webinar	When: 25 <sup>th</sup> June 2025 2024 10am-12pm  Pre-requisites:  1) Read through all pre-webinar materials emailed
Q&A	Webinar	<b>When:</b> 10 <sup>th</sup> September 2025 10am-10.30am
Portfolio submission		15 <sup>th</sup> October 2025 12pm

# 8. FP1 online courses and resources

NICPLD provides a number of online courses and other resources to support FP1 pharmacists in their development. These can be accessed via the NICPLD website, <a href="www.nicpld.org">www.nicpld.org</a>.

# 9. FP1 Educational Supervisor (ES)

Each pharmacist has a workplace Educational Supervisor (ES) to support them through FP1. The ES must be a senior pharmacist with a minimum of 3 years' post-registration experience in pharmacy. They must have completed the NICPLD 'Effective mentoring' online course prior to mentoring an FP1 pharmacist. This can be accessed via the NICPLD website, <a href="https://www.nicpld.org">www.nicpld.org</a>.

The ES will have a supportive role. This involves helping the FP1 pharmacist to identify and meet their learning and development needs and advising and encouraging them during their experiential learning. The roles and responsibilities of the ES are summarised in a checklist for Educational Supervisors. This downloadable checklist and additional information and resources for Educational Supervisors can be accessed via the NICPLD website, <a href="https://www.nicpld.org">www.nicpld.org</a>.

The ES will meet regularly with the FP1 pharmacist but may not necessarily see them every day. Educational Supervisors may sometimes be assisted by local Practice Supervisors who are able to support the FP pharmacist's learning and development and observe their practice on a day-to-day basis.

The ES will be asked to complete a final declaration on the FP1 pharmacist's portfolio submission form to confirm that:

- The pharmacist has satisfactorily completed the four FP1 practice areas.
- The pharmacist's evidence includes two examples of demonstrating accurate performance of calculations in practice.
- The pharmacist has uploaded evidence of completing each practice activity to their portfolio (see section 1 for checklist).
- The pharmacist has mapped evidence to all the learning outcomes in the FP1 portfolio.
- The pharmacist has an assessment rating of 4 at T4 for each of the learning outcomes.

# 10. FP Practice Supervisor (PS)

Some FP1 pharmacists may encounter a number of different Practice Supervisors (PS), particularly in larger workplace establishments. The PS can support the FP1 pharmacist's learning and development and observe their practice on a day-to-day basis. The PS may be asked to sign off some of the FP1 pharmacist's practice activities. It is recommended that Practice Supervisors complete the NICPLD 'Effective workplace training' online course prior to undertaking the role of FP1 trainer. This can be accessed via the NICPLD website, www.nicpld.org.

The roles and responsibilities of the FP1 Practice Supervisor are summarised in a checklist for Practice Supervisors which can be accessed via the NICPLD website, <a href="https://www.nicpld.org">www.nicpld.org</a>.

# 11. FP1 assessment process

The FP1 assessment process will entail a Foundation Portfolio Review (FPR) ONLY. This is described in detail in section 11.1 below.

#### 11.1 Foundation Portfolio Review (FPR)

The FP1 portfolio must be submitted to NICPLD by the specified submission date. Submissions are routinely accepted twice a year, in March and October. Submission dates in 2024/5 will be: 16th October 2024, 19th March 2025 and 15th October 2025. A two-week extension for FP1 portfolio submissions may be given in Exceptional Circumstances, as outlined in the QUB Exceptional Circumstances Categories Guide. Any pharmacist who requires an extension must complete and return a FP1 portfolio extension request form (this can be downloaded from the NICPLD website, <a href="www.nicpld.org">www.nicpld.org</a>) one week before the specified FP1 portfolio submission date. We ask pharmacists to complete an 'Intention to Submit' form in advance of these dates which can be accessed via the NICPLD website, <a href="www.nicpld.org">www.nicpld.org</a>. This allows NICPLD to arrange appropriate assessors and avoid conflicts of interest.

Submitted portfolios will be assessed by a Foundation Assessor who does not work in the same workplace establishment as the FP1 pharmacist. The Foundation Assessor will verify that the FP1 pharmacist has provided sufficient relevant evidence to demonstrate competence against the FP1 learning outcomes. For moderation purposes, a minimum of 10% of portfolios submitted will be double-marked, along with all those portfolios assessed as not meeting the standard by the first assessor (FAIL).

#### All portfolios submitted for FPR must meet these initial standards:

- all practice activities must have been completed;
- the standard expected for each learning outcome (i.e an assessment rating of 4) must have been achieved at the point of submission;
- all learning outcomes must have at least one piece of evidence mapped to it.

Each domain will be assessed according to the grade descriptors outlined below.

Pass	Borderline Pass	Fail
Demonstrates that >70% of the learning outcomes have been met	Demonstrates that 50-70% of the learning outcomes have been met	Demonstrates an insufficient amount of the learning outcomes have been met (<50%)
Shows that patient safety is never jeopardised	Shows that patient safety is never jeopardised	Shows that patient safety is jeopardised*

<sup>\*</sup>If patient safety is compromised by the candidate, they will automatically be awarded a 'Fail' for the domain

#### The FPR process will have two outcomes:

<u>PASS</u> - The candidate achieves a minimum of two pass marks and two borderline marks across the four domains to achieve an overall global pass of the portfolio. Two of the pass marks must be in the person-centred care & collaboration and professional practice domains.

**FAIL** – The candidate will fail the FPR in any of the following circumstances:

- They achieve one or more fail marks across the four domains
- They achieve only one pass mark across the four domains
- They achieve three or more borderline marks across the four domains

• They achieve a mark of borderline or fail in the person-centred care & collaboration and/or professional practice domains.

All portfolios assessed as a 'FAIL' in the first round of assessment will be double marked by a second assessor. If the first and second assessors do not agree on the assessment outcome for the portfolio, they will discuss the portfolio to reach a consensus about the final outcome. In the unlikely event that consensus cannot be reached, the portfolio will be reviewed by an independent assessment panel to agree the final assessment outcome.

If necessary, and at any point in the FPR process, NICPLD will contact the candidate for clarification regarding a piece or pieces of evidence. NICPLD may also contact the ES for clarification or further discussion during or after assessment.

All candidates whose portfolio is assessed as having reached the 'PASS' standard have demonstrated their ability to deliver safe and effective patient care and will be issued with an FP1 Certificate of Achievement. Those candidates whose portfolio has been assessed as 'FAIL' will be provided with feedback on the remedial work required before they can resubmit their portfolio at the next round of FP1 assessments.

# 12. Recognition of Prior Learning (RPL)

NICPLD recognises that registered pharmacists in the existing workforce will have varying degrees of experience in some, or all, of the FP1 practice areas. These individuals can provide a summary of their professional experience (SPE) in those practice area(s) in recognition of their prior learning. There are two RPL pathways:

# RPL pathway 1: Submission of SPE only. Attendance at webinars/workshops is optional.

Pharmacists who believe they can demonstrate that they have already <u>fully covered</u> the FP1 learning outcomes and practice activities can submit a full SPE together with a SPE submission form (which must be signed by your line manager). NICPLD will accept SPE submissions throughout the year. SPE template and the SPE submission form can be found on the NICPLD foundation programme webpages.

NICPLD will assess SPEs to verify that the pharmacist has demonstrated their competence against the FP1 learning outcomes. Each domain will be assessed according to the grade descriptors outlined below:

Pass	Borderline Pass	Fail	
Demonstrates that >70% of the learning outcomes have been met	Demonstrates that 50-70% of the learning outcomes have been met	Demonstrates an insufficient amount of the learning outcomes have been met (<50%)	
Shows that patient safety is never jeopardised	Shows that patient safety is never jeopardised	Shows that patient safety is jeopardised *	

<sup>\*</sup>If patient safety is compromised by the candidate, they will automatically be awarded a 'Fail' for the practice area

The SPE assessment process will have two outcomes:

<u>PASS</u> - The candidate achieves a minimum of two pass marks and two borderline marks across the four domains to achieve an overall global pass of the portfolio. Two of the pass marks must be in the person-centred care & collaboration and professional practice domains.

**FAIL** - The candidate will fail the FPR in any of the following circumstances:

- They achieve one or more fail marks across the four domains
- They achieve only one pass mark across the four domains
- They achieve three or more borderline marks across the four domains
- They achieve a mark of borderline or fail in the person-centred care & collaboration and/or professional practice domains.

If necessary, and at any point in the SPE assessment review process, NICPLD will contact the candidate for clarification regarding a piece or pieces of evidence.

All candidates whose SPE is assessed as having reached the 'PASS' standard have demonstrated their ability to deliver safe and effective patient care and will be issued with an FP1 Certificate of Achievement.

All SPEs assessed as a 'FAIL' will be reviewed by a second assessor. If the first and second assessors do not agree on the assessment outcome for the SPE, they will discuss the SPE to reach a consensus about the final outcome. In the unlikely event that consensus cannot be reached, a third assessor will be asked to review the SPE. Those candidates whose SPE has been assessed as 'FAIL' will be encouraged to join RPL pathway 2 (see below for details). They will be provided with feedback on the remedial work required before they submit their FP1 portfolio for Foundation Portfolio Review (FPR).

# RPL pathway 2: Register onto the FP1 programme to include attendance at webinars and portfolio assessment.

Pharmacists who believe they can demonstrate that they have already <u>partially covered</u> the FP1 learning outcomes and practice activities can write an SPE in the relevant practice area(s). <u>These pharmacists must enrol onto FP1</u> and can upload and use their SPE(s) as a piece or pieces of evidence in their FP1 portfolio. When they have completed their FP1 portfolio, they can submit it for Foundation Portfolio Review (FPR) as outlined in section 11.1. Evidence from the previous 5 years can be used but the following 4 practice activities <u>MUST</u> have been completed as a **registered pharmacist**:

- Medication reviews (OMU)
- Accurate completion of medication records (OMU)
- Accurate provision of person-centred information (OMU)
- Clinical screening (SEPM)

When completing an SPE supportive evidence is not required to be uploaded but it may be requested by the assessor if felt necessary. SPE templates are available on the NICPLD foundation programme webpages.

# 13. Appeals procedure

NICPLD will treat all FP1 pharmacists fairly, equally and with respect in relation to any assessment. If an FP1 pharmacist is dissatisfied with the outcome of their FP1 assessment, they must contact the NICPLD PRFP leads within five working days of their FP1 assessment giving notice of their dissatisfaction and of their intent to forward an appeal. The formal appeals procedure must then be followed:

All appeals against the conduct, adequacy or outcome of an assessment must be forwarded, in writing, to the NICPLD PRFP leads at <a href="mailto:nicpld-PostReg@qub.ac.uk">nicpld-PostReg@qub.ac.uk</a> within 10 working days after the FP1 pharmacist has given notice of their intent. Written support from the FP1 pharmacist's Educational Supervisor (ES) and their Pharmacy Manager must accompany each notification of an appeal.

- On receipt of notification of an appeal, the NICPLD PRFP leads will set a date for the appeal to be heard by an Appeals panel. The Appeals panel will be formed from a sub-group of the PRFP steering group and will consist of personnel not otherwise involved in the appeal. The FP1 pharmacist will be offered the opportunity to be accompanied by another person not involved in the FP1 assessment to help them present their case.
- 2. The Appeals panel will meet within 30 working days of receipt of the written notification of the appeal.
- 3. The Appeals panel will reach a decision and all involved parties will receive verbal notification of the outcome on the day of the appeal and written notification within five working days. This decision will be final.

# 14. Plagiarism

Plagiarism is defined as the presentation of another person's ideas or work and pretending that it is your own<sup>5</sup>. By signing each piece of evidence included in their online portfolio, as well as the learning contract and the portfolio submission form, the FP1 pharmacist is declaring that all work contained within the submitted portfolio is their own.

NICPLD views plagiarism as an offence and, as a centre affiliated with Queen's University Belfast (QUB), conforms to official QUB regulations regarding this offence. All instances of plagiarism, or suspected plagiarism, will be reviewed by the NICPLD PRFP leads, the NICPLD post-reg Associate Postgraduate Pharmacy Dean, and the NICPLD Postgraduate Pharmacy Dean. In addition, as registered pharmacists, FP1 pharmacists and their Educational Supervisors (and Practice Supervisors, where applicable) are expected to abide by the Pharmaceutical Society of Northern Ireland (PSNI) Code of Ethics and Standards. Where appropriate, offences will be communicated to the regulatory body, the Pharmaceutical Society of Northern Ireland (PSNI), for disciplinary measures.

#### 15. NICPLD contact details

For any queries regarding FP1, please email the NICPLD PRFP leads at <u>nicpld-PostRea@aub.ac.uk</u>.

#### 16. References

- 1. Royal Pharmaceutical Society, Post-registration Foundation Pharmacist Curriculum 2021, available at <a href="https://www.rpharms.com">www.rpharms.com</a> (accessed 23.3.2022).
- 2. General Pharmaceutical Council, Standards for the initial education and training of pharmacists 2021, available at <a href="https://www.pharmacyregulation.org">www.pharmacyregulation.org</a> (accessed 23.3.2022).
- 3. Daniels, H. 2001, Vygotsky and Pedagogy, Routledge Falmer, London.

	Royal Pharmaceutical Society, Building your portfolio - quality evidence, Forsyth, P., 2022, Lead Pharmacist Clinical Cardiology, NHS Greater Glasgow & Clyde.		
Э.	Collins Dictionary 2022, available at <a href="https://www.collinsdictionary.com/dictiona">www.collinsdictionary.com/dictiona</a>	ry/english/plagiarism (accessed 12.4.2022).	
	F	Page 19	